Lambasted by AIDS activists about Truvada pricing, Gilead offers CDC drug supply deal; FibroGen MACE miscommunication leaves investors disoriented
→ Chastised by AIDS activists for its pricing policy on Truvada, Gilead $GILD has agreed to provide to CDC with up to 2.4 million bottles of the HIV-prevention pill annually for uninsured Americans at risk for HIV. The donation, which extends up to 2030, will transition to Descovy if it is approved for use as a preventative treatment or PrEP (pre-exposure prophylaxis), in which individuals at high risk for HIV take medicines daily to lower their chances of contracting the infection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.